Prescription Revision's Podcast

 Dr Paul Ryan will discuss two main pharmacological agents used to treat hypertension, RAAS inhibitors & calcium channel blockers. 

Dr Paul Ryan will discuss how hypertension is diagnosed and how Stage 1 and Stage 2 hypertension are defined. He will also discuss the management of both Stage 1 and Stage 2 hypertension.

Dr Paul Ryan will discuss the next steps after repeat clinic BP reading remains >140/90mmHg  as per current NICE, ESC, ESH, ACC, and AHA guidelines including, ABPM monitoring, specific blood tests & urinary investigations. He will also discuss what specifically to look for on ECG.

Dr Paul Ryan will discuss high altitude illness, zika virus, cholera, tick-borne encephalitis, Japanese encephalitis & paediatric travel vaccines.

Dr Paul Ryan will discuss yellow fever, hepatitis B, rabies & meningitis ACWY.

Dr Paul Ryan will discuss general advice given to those travelling abroad, traveller's diarrhoea, mosquito avoidance, malaria prophylaxis & travel vaccines.

Dr Paul Ryan will discuss sulphonylureas & pioglitazones. He will also discuss the follow-up with diabetic patients and a memory aid that can be used in deciding on appropriate treatment after metformin.

Dr Paul Ryan will discuss the use of oral hypoglycaemics & their effect on patients weight. He will also discuss SGLT2s, incretin-based therapies & current diabetes guidelines on cardiovascular outcomes.

Dr Paul Ryan will discuss the main classes of hypoglycaemic agents, their efficacy & tips for prescribing different agents. He will also discuss patients with raised BMI & established cardiovascular disease & HbA1c targets.

Dr Paul Ryan will discuss the definition & diagnosis of type 2 diabetes. He will also discuss at what HbA1c does treatment need to be started, why metformin is the first-line treatment & the side effects of Metformin.

Dr Paul Ryan will discuss a number of Cochrane reviews published in the last few years that looked at the efficacy of antibiotics in common respiratory tract infections.

Dr Paul Ryan will discuss the use of delayed back-up antimicrobial prescriptions which are used where there is clinical uncertainty as to whether the condition is self-limiting or is likely to deteriorate.

Dr Paul Ryan will discuss how to approach a request for an antibiotic & how to put shared decision-making into practice regarding the prescribing of antibiotics. He will firstly discuss why antibiotics are prescribed.

Dr Paul Ryan will discuss heart failure with preserved ejection fraction (HFpEF).

Dr Paul Ryan will discuss the role of SGLT2s in chronic heart failure.

Dr Paul Ryan will discuss the role of ARNIs in patients with heart failure with reduced ejection fraction.

Dr Paul Ryan will discuss the role of diuretics in chronic heart failure with reduced ejection fraction.

Dr Paul Ryan will discuss the role of beta blockers in patients with chronic heart failure, their mechanism of action & starting treatment with beta blockers.

Dr Paul Ryan will discuss the prevalence & causes of heart failure, ejection fraction &  prognosis for those patients with heart failure. 

Dr Paul Ryan will discuss ACE inhibitors' mechanism of action, the practicalities of starting patients on ACE inhibitors & the four main adverse effects associated with ACE inhibitors.

Dr Paul Ryan will discuss the non-pharmacological management in patients with heart failure with reduced ejection fraction & the steps of pharmacological management. He will also look at the current international guidelines on the management of patients with heart failure.

Dr Paul Ryan will discuss the introduction to solid foods in babies with GORD, red flags associated with GORD & risk factors for GORD.

Dr Paul Ryan will discuss the history, exam & investigations for heart failure. He will also briefly discuss the New York Heart Association functional classification.

Dr Paul Ryan will discuss NOAC dose adjustments in non-valvular atrial fibrillation.

Dr Paul Ryan will discuss the general management of GORD in both breastfed and bottle-fed babies, along with the pharmacological therapy used to manage GORD.